Advertisement

Topics

[Comment] Opioid addiction: long-acting formulations for a long-term disorder

19:50 EST 18 Feb 2019 | The Lancet

Barbara Haight and colleagues1 report findings from their phase 3 trial, providing evidence that a novel, monthly, long-acting buprenorphine formulation (BUP-XR) is both safe and efficacious in reducing illicit opioid use, compared with placebo. Extended-release buprenorphine (Sublocade; Indivior, Richmond, VA, USA), given as monthly injections, is the latest drug approved for opioid use disorders by the US Food and Drug Administration.2

Original Article: [Comment] Opioid addiction: long-acting formulations for a long-term disorder

NEXT ARTICLE

More From BioPortfolio on "[Comment] Opioid addiction: long-acting formulations for a long-term disorder"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...